Liposomal Irinotecan, S-1, and Oxaliplatin in Advanced Pancreatic Adenocarcinoma
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
In present study, the investigators evaluate the safety and efficacy of OIS-derived NASOX
regimen (nal-IRI, S-1, oxaliplatin) in advanced pancreatic cancer. NASOX regimen contains
nal-IRI, which has recently been proven effective in pancreatic cancer.